Log In
BCIQ
Print this Print this
 

Rencarex, girentuximab (formerly WX-G250)

  Manage Alerts
Collapse Summary General Information
Company Wilex AG
DescriptionChimeric mAb against carbonic anhydrase IX (CAIX)
Molecular Target Carbonic anhydrase IX (CAIX)
Mechanism of ActionAntibody; Antibody dependent cellular cytotoxicity (ADCC)
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationRenal cancer
Indication DetailsTreat clear cell renal cell carcinoma (RCC); Treat non-metastatic clear cell renal cell carcinoma (ccRCC); Treat renal cancer
Regulatory Designation U.S. - Fast Track (Treat clear cell renal cell carcinoma (RCC));
U.S. - Orphan Drug (Treat renal cancer);
EU - Orphan Drug (Treat renal cancer)
PartnerEsteve S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$21.1M

$39.0M

$14.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/09/2011

Undisclosed

$39.0M

Undisclosed

01/12/2009

$21.1M

0

$14.0M

Get a free BioCentury trial today